EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review
02:40 EDT 19 Jul 2012 | The Medical News
Pfizer Inc. today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for..
Original Article: EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review
More From BioPortfolio on "EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
